There are no related discussions.
Genzyme’s woes continue as it drops investigational APB follow-up for Renvela, after poor trial results
Article | 19 November 2009
US biotechnology major Genzyme has reported results of a Phase II/III study of its advanced phosphate binder (APB), a stronger version of its already-marketed kidney disease drug Renvela (sevelamer carbonate), which met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo in patients with chronic kidney disease. However, the APB did not show a significant improvement in phosphate lowering compared to Renvela.
Based on these results, the company is not planning to pursue further clinical development of the new APB. Genzyme was seeking to develop a product with higher potency that would more effectively bind phosphate, while maintaining
all the benefits of Renvela.
Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.
Looking to plug patent gapGenzyme had hoped to get the new APB approved before patents on Renvela and its predecessor Renagel (sevelamer) expire in 2014. These two products generated combined sales of $680 million in 2008. The news also comes swiftly on the back of production facility problems for five of the US firm’s drugs for rare diseases and an approval delay for another (The Pharma Marketletters November 16 and 17).
In the study, Renvela and the APB both effectively lowered patients’ phosphorus levels. Most adverse events associated with both Renvela and the APB were mild in nature, and the most frequently reported events were gastrointestinal disorders.
The trial was a randomized, double-blind, placebo-controlled study that enrolled 349 adult hemodialysis patients with hyperphosphatemia. It included seven arms: low, medium and high dose APB; low, medium and high dose Renvela, and placebo. It included a two-week screening period, a two-week washout period, and a three-week treatment period.
The latest discussion & debate from thepharmaletter.com discussion forums...
Gas Generators V Gas Cylinders
Peak Scientific Instruments have been established as a pioneer in Gas Generation since 1973 we are known worldwide for our excellent product range of on site gas generation
Promoting 'Safety and Efficiency in the Laboratory Environment.
Peak Scientific Instruments have a mission - to replace all cylinders. As a manufacturer of laboratory nitrogen, hydrogen & zero air gas generators they want to make everyone aware of the dangers & inconveniences of combustible gas cylinders. A Peak gas generator offers the safer solution to your gas needs by eliminating cylinders in the lab. Stop yourself worrying about the safe handling of gases, the safety valves, the explosion risk, the storage, the re-ordering & all the other things that go along with being a cylinder user - replace your cylinders with a safe, economical, endless supply of gas from a Peak generator.
Call Maureen on 0141 530 4168 or visit www.peakscientific.com
2010-01-28 09:33:10
Here just we are itroducing ourself.Barat Bioinformatics Research Institute (BBRI) is consultancy and service provider in the field of Bioinformatics and Information Technology. We aim at delivering innovative and customized Insilico solutions matched to the special needs of biotechnological and pharmaceutical origin. And we can deliever at intime datamining works.
contact
nagireddy@bbri.in visit us at www.bbri.in
2009-12-14 05:41:17
Hi all,
Apologies for the product placement here, but we just wanted to introduce ourselves. We host a lot of pharmaceutical conferences and would love to host more! If you are looking for a venue for a meeting, conference or event, Nottingham Conferences offers four flexible venues with excellent facilities, do get in touch if you are interested.
Give us a call on 0115 846 8000, visit www.nottinghamconferences.co.uk, or e-mail us at conferences@nottingham.ac.uk.
Thanks again for your time.
Kirstie
2009-12-11 11:05:02
